联用白介素-2与顺铂治疗恶性胸腔积液的效果探析

Efficacy of cisplatin combined with interleukin-2 in the treatment of malignant pleural effusion

目的 :探究联合使用白介素-2与顺铂治疗恶性胸腔积液的临床效果。方法 :选取2015年6月22日至2016年6月22日期间南溪区人民医院收治的100例恶性胸腔积液患者作为研究对象。采用抽签分组法将这些患者平均分为白介素-2组(n=50)和地塞米松组(n=50)。对白介素-2组患者联用白介素-2与顺铂进行胸腔内注射治疗;对地塞米松组患者联用地塞米松与顺铂进行胸腔内注射治疗。治疗结束后,观察两组患者发生不良反应的情况、治疗的效果、在接受治疗前和接受治疗后2周、4周、8周使用卡氏评分法(Karnofsky,KPS)评价其生存质量评分的情况以及在接受治疗后6个月和12个月其发生死亡的情况。结果 :接受治疗后,白介素-2组患者不良反应的总发生率明显低于地塞米松组患者,其治疗的总有效率明显高于地塞米松组患者,差异具有统计学意义(P<0.05)。在接受治疗前,两组患者的Karnofsky评分相比,差异无统计学意义(P>0.05)。在接受治疗后2周、4周和8周,两组患者的Karnofsky评分与其接受治疗前相比均有明显的提高,且白介素-2组患者Karnofsky评分提高的幅度更为明显,差异具有统计学意义(P<0.05)。在接受治疗后6个月和12个月,白介素-2组患者的死亡率均明显低于地塞米松组患者,差异具有统计学意义(P<0.05)。结论:联用白介素-2与顺铂治疗恶性胸腔积液的效果显著,可有效地改善患者的生存质量,延长其生存时间,且安全性较高。

Objective： To analyze the efficacy of cisplatin combined with interleukin-2 in the treatment of malignant pleural effusion. Methods： Select 100 cases of malignant pleural effusion treated in People＇s Hospital of Nanxi District during June 22th 2015 to June 22th 2016 for research object. Randomly divide the patients to interleukin – 2 group（n=50） and dexamethasone group（n=50）. Treat interleukin – 2 group with intrapleural injection of interleukin – 2 combined with cisplatin, treat dexamethasone group with intrapleural injection of dexamethasone combined with cisplatin. After treatment, observe occurrence of adverse reactions,total effective rate, KPS in pre-treatment and 2nd weeks,4th week,8th week of treatment process and mortality rate in 6th month,12th month after treatment. Results： After treatment, occurrence of adverse reactions of interleukin – 2 group is lower than that in control group（ P 0.05）. Before treatment, the difference of KPS between 2 groups have no statistical significant（P 0.05）. In 2nd weeks,4th week,8th week of treatment process, KPS of 2 groups are increased, and KPS of interleukin – 2 group were increased more（P 0.05）.In 6th month,12th month after treatment, mortality rate of interleukin – 2 group is lower than that in control group（ P 0.05）.Conclusion： The efficacy of cisplatin combined with interleukin-2 in the treatment of malignant pleural effusion is significant, it will improve life quality of patients, lengthen their survival time,and safety is high.